Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study

Gemma Bruera; Silvia Massacese; Stefania Candria; Antonio Galvano; Rosa Manetta; Aldo Victor Giordano; Sergio Carducci; Alessandra Di Sibio; Eugenio Ciacco; Antonio Russo; Enrico Ricevuto;

doi:10.18632/oncotarget.25870

Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study

Oncotarget ◽

10.18632/oncotarget.25870 ◽

2018 ◽

Vol 9 (61) ◽

pp. 31861-31876 ◽

Cited By ~ 2

Author(s):

Gemma Bruera ◽

Silvia Massacese ◽

Stefania Candria ◽

Antonio Galvano ◽

Rosa Manetta ◽

...

Keyword(s):

Pancreatic Ductal Adenocarcinoma ◽

Phase Ii ◽

Phase Ii Study ◽

Real Life ◽

Ductal Adenocarcinoma ◽

First Line

Download Full-text

Real life triplet FIr/FOx chemotherapy in first line metastatic pancreatic ductal adenocarcinoma: Recommended schedule for expected activity and safety and phase II study

Annals of Oncology ◽

10.1093/annonc/mdy151.153 ◽

2018 ◽

Vol 29 ◽

pp. v43

Author(s):

G. Bruera ◽

S. Massacese ◽

R. Manetta ◽

A. Giordano ◽

S. Carducci ◽

...

Keyword(s):

Pancreatic Ductal Adenocarcinoma ◽

Phase Ii ◽

Phase Ii Study ◽

Real Life ◽

Ductal Adenocarcinoma ◽

First Line

Download Full-text

LBA65 The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.2300 ◽

2020 ◽

Vol 31 ◽

pp. S1195

Author(s):

D.J. Renouf ◽

J.J. Knox ◽

P. Kavan ◽

D. Jonker ◽

S. Welch ◽

...

Keyword(s):

Pancreatic Ductal Adenocarcinoma ◽

Phase Ii ◽

Phase Ii Study ◽

Ductal Adenocarcinoma ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Randomized Phase Ii ◽

Cancer Trials

Download Full-text

KRAS Mutation in Metastatic Pancreatic Ductal Adenocarcinoma: Results of a Multicenter Phase II Study Evaluating Efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Therapy

Oncology ◽

10.1159/000330194 ◽

2011 ◽

Vol 81 (1) ◽

pp. 3-8 ◽

Cited By ~ 32

Author(s):

F. Kullmann ◽

A. Hartmann ◽

R. Stöhr ◽

H. Messmann ◽

M.M. Dollinger ◽

...

Keyword(s):

Pancreatic Ductal Adenocarcinoma ◽

Phase Ii ◽

Kras Mutation ◽

Phase Ii Study ◽

Ductal Adenocarcinoma ◽

First Line ◽

First Line Therapy ◽

Multicenter Phase ◽

Line Therapy

Download Full-text

Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX).

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.4107 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 4107-4107 ◽

Cited By ~ 5

Author(s):

Julien Taieb ◽

Yves Rinaldi ◽

Anne-Laure Pointet ◽

Emilie Barbier ◽

Faiza Khemissa ◽

...

Keyword(s):

Pancreatic Ductal Adenocarcinoma ◽

Phase Ii ◽

Phase Ii Study ◽

Ductal Adenocarcinoma ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

A phase II study of pre- and post-operative gemcitabine and erlotinib plus pancreaticoduodenectomy (PD) for patients with resectable pancreatic ductal adenocarcinoma (PDAC): ACOSOG Z5041 trial (Alliance).

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.4112 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 4112-4112

Author(s):

Alice Chia-chi Wei ◽

Fang-Shu Ou ◽

Qian Shi ◽

Eileen Mary O'Reilly ◽

Jeffrey A. Meyerhardt ◽

...

Keyword(s):

Pancreatic Ductal Adenocarcinoma ◽

Phase Ii ◽

Phase Ii Study ◽

Ductal Adenocarcinoma

Download Full-text

A randomized phase II study of maintenance therapy with multiepitope vaccine tedopi (OSE2101) ± nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaM – PRODIGE 63 GERCOR study)

Annals of Oncology ◽

10.1093/annonc/mdz247.156 ◽

2019 ◽

Vol 30 ◽

pp. v318-v319

Author(s):

C. Neuzillet ◽

V. Hautefeuille ◽

A. Lambert ◽

M.-L. Garcia-Larnicol ◽

D. Vernerey

Keyword(s):

Maintenance Therapy ◽

Pancreatic Ductal Adenocarcinoma ◽

Induction Chemotherapy ◽

Phase Ii ◽

Phase Ii Study ◽

Ductal Adenocarcinoma ◽

Randomized Phase Ii

Download Full-text

Faculty Opinions recommendation of HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732284626.793571311 ◽

2020 ◽

Author(s):

Jordan Berlin

Keyword(s):

Pancreatic Ductal Adenocarcinoma ◽

Phase Ii ◽

Phase Ii Study ◽

Ductal Adenocarcinoma ◽

Randomized Phase Ii

Download Full-text

Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S‐1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma

The Oncologist ◽

10.1634/theoncologist.2018-0900 ◽

2019 ◽

Vol 24 (6) ◽

pp. 749 ◽

Cited By ~ 3

Author(s):

Takahiro Akahori ◽

Masayuki Sho ◽

Hiroaki Yanagimoto ◽

Sohei Satoi ◽

Minako Nagai ◽

...

Keyword(s):

Pancreatic Ductal Adenocarcinoma ◽

Phase Ii ◽

Combination Chemotherapy ◽

Phase Ii Study ◽

Ductal Adenocarcinoma ◽

Triple Combination

Download Full-text

Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis

Annals of Surgery ◽

10.1097/sla.0000000000001705 ◽

2017 ◽

Vol 265 (2) ◽

pp. 397-401 ◽

Cited By ~ 38

Author(s):

Sohei Satoi ◽

Tsutomu Fujii ◽

Hiroaki Yanagimoto ◽

Fuyuhiko Motoi ◽

Masanao Kurata ◽

...

Keyword(s):

Pancreatic Ductal Adenocarcinoma ◽

Phase Ii ◽

Peritoneal Metastasis ◽

Phase Ii Study ◽

Ductal Adenocarcinoma ◽

Multicenter Phase

Download Full-text

Initial survival outcomes for the AGITG GAP study – a phase II study of perioperative nab-paclitaxel and gemcitabine for resectable pancreatic ductal adenocarcinoma (PDAC).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.4105 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 4105-4105 ◽

Cited By ~ 3

Author(s):

Andrew Barbour ◽

Nicholas O'Rourke ◽

Howard Chan ◽

Yu Jo Chua ◽

James Kench ◽

...

Keyword(s):

Pancreatic Ductal Adenocarcinoma ◽

Phase Ii ◽

Phase Ii Study ◽

Ductal Adenocarcinoma ◽

Survival Outcomes

Download Full-text